Form 4: CFO Kelly's RSU Vesting and Tax-Related Stock Sale

Precision Biosciences CFO John Alexander Kelly reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Chief Financial Officer John Alexander Kelly acquired 27,584 shares of Precision Biosciences Common Stock on February 17, 2026, through the vesting of Restricted Stock Units (RSUs).
• On February 18, 2026, Kelly sold 8,149 shares of Common Stock at a price of $3.84 per share.
• This sale was a 'sell-to-cover' transaction, executed under a Rule 10b5-1 plan adopted on January 17, 2025, solely to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Kelly directly beneficially owns 125,883 shares of Common Stock and 55,166 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects routine executive compensation and tax management, rather than a discretionary sale indicating a lack of confidence.

Positives

• The vesting of Restricted Stock Units indicates continued compensation and retention of a key executive.
• The sale was explicitly for tax purposes (sell-to-cover), not a discretionary sale by the CFO, which typically signals confidence in the company.

Negatives

• A portion of shares were sold, reducing the CFO's direct ownership, although this was a non-discretionary transaction for tax purposes.

Risks

• NA

Future Outlook

The filing indicates future RSU vesting installments for the reporting person, with RSUs vesting in three substantially equal annual installments beginning on February 17, 2026, subject to continued service.

Management Comments

• The sale of shares was solely to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units.
• The reporting person did not sell or otherwise dispose of shares for any reason other than to cover required taxes and fees.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions following RSU vesting are a common practice among executives to manage tax liabilities without indicating a discretionary change in their investment outlook for the company. This is a routine insider transaction for a biotechnology company like Precision Biosciences.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across industries, including biotechnology, for executives receiving equity compensation.
• The adoption of a Rule 10b5-1 plan on January 17, 2025, aligns with best practices for insiders to pre-arrange stock transactions and avoid accusations of trading on material non-public information.
• This is comparable to similar practices seen at companies like Moderna or Pfizer where executives manage their equity compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and tax management, not indicative of a change in company fundamentals or executive confidence.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Future vesting of remaining Restricted Stock Units in substantially equal annual installments beginning February 17, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sell-to-cover for tax purposes. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The transaction is pre-planned under a Rule 10b5-1 plan, further indicating its non-discretionary nature. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for significant price movement or a re-evaluation of the company's intrinsic value.

Keywords

Precision Biosciences, DTIL, Form 4, Insider Trading, John Alexander Kelly, CFO, Restricted Stock Units, RSU Vesting, Sell-to-Cover, Rule 10b5-1